PE20191323A1 - PIRAZOLO[3,4-b]PIRIDINAS E IMIDAZO[1,5-b]PIRIDAZINAS COMO INHIBIDORES DE PDE1 - Google Patents
PIRAZOLO[3,4-b]PIRIDINAS E IMIDAZO[1,5-b]PIRIDAZINAS COMO INHIBIDORES DE PDE1Info
- Publication number
- PE20191323A1 PE20191323A1 PE2019001294A PE2019001294A PE20191323A1 PE 20191323 A1 PE20191323 A1 PE 20191323A1 PE 2019001294 A PE2019001294 A PE 2019001294A PE 2019001294 A PE2019001294 A PE 2019001294A PE 20191323 A1 PE20191323 A1 PE 20191323A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrazolo
- methyl
- branched
- alkyl
- linear
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 150000004892 pyridazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- FOVDMANDBXNDTK-UHFFFAOYSA-N 6-(2-ethoxypyridin-3-yl)-1-methyl-N-[(1-methylimidazol-4-yl)methyl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-4-amine Chemical compound C(C)OC1=NC=CC=C1C=1C=C(C2=C(N=1)N(N=C2C(C)C)C)NCC=1N=CN(C=1)C FOVDMANDBXNDTK-UHFFFAOYSA-N 0.000 abstract 1
- WYHCKHHDBOXJTM-UHFFFAOYSA-N 6-(2-ethoxypyridin-3-yl)-1-methyl-N-[(2-methyl-1,3-oxazol-4-yl)methyl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-4-amine Chemical compound C(C)OC1=NC=CC=C1C=1C=C(C2=C(N=1)N(N=C2C(C)C)C)NCC=1N=C(OC=1)C WYHCKHHDBOXJTM-UHFFFAOYSA-N 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600784 | 2016-12-22 | ||
| DKPA201700404 | 2017-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191323A1 true PE20191323A1 (es) | 2019-09-24 |
Family
ID=60812077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001294A PE20191323A1 (es) | 2016-12-22 | 2017-12-20 | PIRAZOLO[3,4-b]PIRIDINAS E IMIDAZO[1,5-b]PIRIDAZINAS COMO INHIBIDORES DE PDE1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10351561B2 (enExample) |
| EP (1) | EP3558988B1 (enExample) |
| JP (1) | JP7074758B2 (enExample) |
| KR (1) | KR20190095301A (enExample) |
| CN (1) | CN110099901B (enExample) |
| AU (1) | AU2017384481A1 (enExample) |
| BR (1) | BR112018017067A2 (enExample) |
| CA (1) | CA3046588A1 (enExample) |
| CL (1) | CL2019001669A1 (enExample) |
| CO (1) | CO2019005538A2 (enExample) |
| CR (1) | CR20190302A (enExample) |
| DO (1) | DOP2019000169A (enExample) |
| EC (1) | ECSP19043790A (enExample) |
| ES (1) | ES2882335T3 (enExample) |
| IL (1) | IL267561A (enExample) |
| JO (1) | JOP20190126A1 (enExample) |
| MX (1) | MX2019007509A (enExample) |
| PE (1) | PE20191323A1 (enExample) |
| PH (1) | PH12019501324A1 (enExample) |
| RU (1) | RU2019116251A (enExample) |
| TW (1) | TW201829405A (enExample) |
| WO (1) | WO2018115067A1 (enExample) |
| ZA (1) | ZA201904236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| HRP20211784T1 (hr) | 2017-12-14 | 2022-02-18 | H. Lundbeck A/S | Kombinacijski tretmani koji se sastoje od primjene 1h-pirazolo[4,3-b]piridina |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| EP3728250A1 (en) | 2017-12-20 | 2020-10-28 | H. Lundbeck A/S | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| AU2020412779A1 (en) * | 2019-12-23 | 2022-06-23 | Sanford Burnham Prebys Medical Discovery Institute | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| EP1763528B1 (en) * | 2004-07-05 | 2008-11-26 | Astellas Pharma Inc. | Pyrazolopyridine derivatives |
| EP1802621B1 (en) | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
| JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| DK2124944T3 (da) | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer |
| WO2009067607A2 (en) * | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| EA201170773A1 (ru) * | 2008-12-06 | 2012-01-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2013142307A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics | Carbamate compounds and of making and using same |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| CA2961186A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| WO2016147659A1 (en) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| TW201643167A (zh) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2017
- 2017-06-16 JO JOP/2019/0126A patent/JOP20190126A1/ar unknown
- 2017-12-19 TW TW106144606A patent/TW201829405A/zh unknown
- 2017-12-20 AU AU2017384481A patent/AU2017384481A1/en not_active Abandoned
- 2017-12-20 WO PCT/EP2017/083721 patent/WO2018115067A1/en not_active Ceased
- 2017-12-20 MX MX2019007509A patent/MX2019007509A/es unknown
- 2017-12-20 BR BR112018017067A patent/BR112018017067A2/pt not_active Application Discontinuation
- 2017-12-20 RU RU2019116251A patent/RU2019116251A/ru not_active Application Discontinuation
- 2017-12-20 CN CN201780079553.2A patent/CN110099901B/zh not_active Expired - Fee Related
- 2017-12-20 CA CA3046588A patent/CA3046588A1/en not_active Abandoned
- 2017-12-20 PE PE2019001294A patent/PE20191323A1/es unknown
- 2017-12-20 ES ES17821622T patent/ES2882335T3/es active Active
- 2017-12-20 CR CR20190302A patent/CR20190302A/es unknown
- 2017-12-20 KR KR1020197017840A patent/KR20190095301A/ko not_active Ceased
- 2017-12-20 EP EP17821622.2A patent/EP3558988B1/en active Active
- 2017-12-20 JP JP2019534197A patent/JP7074758B2/ja active Active
- 2017-12-21 US US15/849,798 patent/US10351561B2/en active Active
-
2019
- 2019-05-28 CO CONC2019/0005538A patent/CO2019005538A2/es unknown
- 2019-05-29 US US16/424,585 patent/US10689379B2/en active Active
- 2019-06-11 PH PH12019501324A patent/PH12019501324A1/en unknown
- 2019-06-17 CL CL2019001669A patent/CL2019001669A1/es unknown
- 2019-06-18 DO DO2019000169A patent/DOP2019000169A/es unknown
- 2019-06-19 EC ECSENADI201943790A patent/ECSP19043790A/es unknown
- 2019-06-20 IL IL267561A patent/IL267561A/en unknown
- 2019-06-27 ZA ZA2019/04236A patent/ZA201904236B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019005538A2 (es) | 2019-06-11 |
| ZA201904236B (en) | 2020-12-23 |
| DOP2019000169A (es) | 2019-07-31 |
| ES2882335T3 (es) | 2021-12-01 |
| CN110099901B (zh) | 2023-01-03 |
| ECSP19043790A (es) | 2019-06-30 |
| TW201829405A (zh) | 2018-08-16 |
| PH12019501324A1 (en) | 2019-09-16 |
| JOP20190126A1 (ar) | 2019-05-28 |
| EP3558988B1 (en) | 2021-07-07 |
| US10351561B2 (en) | 2019-07-16 |
| CL2019001669A1 (es) | 2019-09-06 |
| RU2019116251A3 (enExample) | 2021-03-31 |
| US10689379B2 (en) | 2020-06-23 |
| CR20190302A (es) | 2019-08-21 |
| CN110099901A (zh) | 2019-08-06 |
| WO2018115067A1 (en) | 2018-06-28 |
| MX2019007509A (es) | 2019-09-04 |
| JP2020502230A (ja) | 2020-01-23 |
| EP3558988A1 (en) | 2019-10-30 |
| JP7074758B2 (ja) | 2022-05-24 |
| CA3046588A1 (en) | 2018-06-28 |
| AU2017384481A1 (en) | 2019-06-13 |
| IL267561A (en) | 2019-08-29 |
| BR112018017067A2 (pt) | 2019-07-02 |
| US20180179200A1 (en) | 2018-06-28 |
| KR20190095301A (ko) | 2019-08-14 |
| RU2019116251A (ru) | 2021-01-22 |
| US20190352302A1 (en) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191323A1 (es) | PIRAZOLO[3,4-b]PIRIDINAS E IMIDAZO[1,5-b]PIRIDAZINAS COMO INHIBIDORES DE PDE1 | |
| MX372934B (es) | Compuestos de imidazopiridina y sus usos. | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20171179A1 (es) | Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20171514A1 (es) | Heterociclos biciclicos como inhibidores de fgfr | |
| AR089424A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| PE20191496A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| PE20170693A1 (es) | Derivados de imidazol pentaciclicos fusionados | |
| PE20230731A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
| EP3577116A4 (en) | Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as thereapeutic agents | |
| AR086589A1 (es) | Compuestos imidazopiridina | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20081612A1 (es) | Analogos de las pterinas | |
| PE20161021A1 (es) | Derivados heterociclicos biciclicos como inhibidores de bromodominio | |
| PE20140970A1 (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| SV2011003997A (es) | Pirimidinas fusionadas |